{"id":"084bfef9-162f-4bfd-86ad-8087ffb9b4b3","url":"content/084bfef9-162f-4bfd-86ad-8087ffb9b4b3","title":"Overview","outline":"/publication/75bfaa02-cc71-4a79-a7dd-dbc47541edea/outline","content":{"mime":"application/xml","data":"<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<!-- content-type_s: --><!-- Generated by cjs2htmlbase.xsl--><div data-ot-plugin=\"com.congility.html\" lang=\"en\" role=\"main\" xmlns:astX=\"http://www.astoriasoftware.com/translation\"><div class=\"topic service-user-information commentable-section\" data-annot-id=\"topic.dita_34c9bbe8-61ef-48db-81d0-5fcdd3e8c5f3\" id=\"topic.dita_34c9bbe8-61ef-48db-81d0-5fcdd3e8c5f3\"><article aria-labelledby=\"ariaid-title1\" role=\"article\">\n  \n  \n  <div class=\"body service-user-information-body\">\n    <p class=\"p\">This information is intended to support healthcare professionals when having conversations with people with early and locally advanced breast cancer about having adjuvant treatment with trastuzumab. It will help them reach a shared decision together, based on NICEâ€™s recommendations. </p>\n  </div>\n</article></div></div>"},"metadata":{},"solr":{"custom":{},"doc":{"href_s":"SD00835146","url_s":"content/084bfef9-162f-4bfd-86ad-8087ffb9b4b3","title_s":"Overview","nextTopic_s":"a384e02b-54b2-4c76-81b6-2af89dfa611f","prevTopic_s":"31f461ce-1969-4caf-b0fc-b989dc4af471"},"nice":{"nice_infotype_s":"service-user-information","nice_guideline-id_s":"","nice_content-id_s":"","nice_content-type_s":""}},"contentObject":{"publicationuuid":"75bfaa02-cc71-4a79-a7dd-dbc47541edea","contentuuid":"084bfef9-162f-4bfd-86ad-8087ffb9b4b3","contentjoinuuid":"189766dd-2048-4c5b-8f32-73d371cea9b5","contentjoinuuids":["189766dd-2048-4c5b-8f32-73d371cea9b5","b6411394-b182-48a0-932b-feab3de553ac"],"publicationjoinuuid":"356cbf6a-a380-418a-9856-781ae39f6dca"}}